09:04 AM EDT, 07/31/2025 (MT Newswires) -- CVS Health ( CVS ) lifted its full-year outlook on Thursday as the healthcare company reported second-quarter results above Wall Street's estimates amid double-digit revenue gains across all segments.

Adjusted earnings are now expected to be in a range of $6.30 to $6.40 per share for 2025, up from the company's previous guidance of $6 to $6.20. The firm anticipates revenue of at least $391.5 billion for the year, compared with the prior forecast of at least $382.6 billion, according to an earnings presentation. The current consensus on FactSet is for non-GAAP EPS of $6.12 and sales of $386.78 billion.

The stock rose 6.8% in the most recent premarket activity.

"We are encouraged by a second consecutive quarter of solid 2025 results, while we continue to navigate a dynamic environment," Chief Financial Officer Brian Newman said in a statement. "As we execute against our strategic priorities, we remain focused on delivering on our financial commitments and advancing initiatives that create long-term value for our stakeholders."

For the June quarter, CVS Health's ( CVS ) adjusted EPS declined to $1.81 from $1.83 the year before, but exceeded the Street's view for $1.46. Revenue climbed 8.4% to $98.92 billion, ahead of the average analyst estimate of $94.51 billion.

Sales in the company's health care benefits segment advanced 12% to $36.26 billion, buoyed by gains in the government business, mainly due to the impact of the inflation reduction act on the Medicare Part D program, it said.

The division's medical benefit ratio increased to 89.9% from 89.6% in the prior-year quarter due to a $471 million premium deficiency reserve, recorded as health care costs in its Medicare Advantage product line associated with anticipated losses for the remainder of the current coverage year. A lower ratio likely indicates higher profitability.

Health services revenue inclined 10% to $46.45 billion, strengthened by pharmacy drug mix and brand inflation. Pharmacy and consumer wellness sales rose about 13% to $33.58 billion, boosted by increased prescription and front store volume, among other factors.

"Our strong performance demonstrates the continued focus we have on operational and financial improvement across our businesses, led by a significant and durable recovery at Aetna, strong retention at CVS Caremark and growth and momentum at CVS Pharmacy," Chief Executive David Joyner said.